National Drug Schedules

when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other ingredients; or b) for human or veterinary use as a single ingredient intended for any route of administration other than oral

When recommended for parenteral use as a tissue sclerosing agent.

For human use - when sold for the treatment of hyperphosphatemia.

Including but not limited to teriflunomide. 

For human use. 

When sold for the treatment of primary or secondary levocarnitine deficiency.

For human use - when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher.

for otic use

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

Including but not limited to: Clindamycin 

For human use. 

Including but not limited to Lodoxamide tromethamine.

For veterinary use.

Except in oral dosage form that provides 1 milligram (mg) or less per daily dose.